JP2015523986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523986A5 JP2015523986A5 JP2015516113A JP2015516113A JP2015523986A5 JP 2015523986 A5 JP2015523986 A5 JP 2015523986A5 JP 2015516113 A JP2015516113 A JP 2015516113A JP 2015516113 A JP2015516113 A JP 2015516113A JP 2015523986 A5 JP2015523986 A5 JP 2015523986A5
- Authority
- JP
- Japan
- Prior art keywords
- laquinimod
- pharmaceutically acceptable
- acceptable salt
- effective amount
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 57
- 229960004577 laquinimod Drugs 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 35
- 208000027866 inflammatory disease Diseases 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 206010046851 Uveitis Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 7
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 7
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 210000003979 eosinophil Anatomy 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000004087 cornea Anatomy 0.000 claims description 5
- 210000000744 eyelid Anatomy 0.000 claims description 5
- 210000001525 retina Anatomy 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 4
- 210000004561 lacrimal apparatus Anatomy 0.000 claims description 4
- 206010010755 Conjunctivitis viral Diseases 0.000 claims description 3
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims description 3
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010067671 Disease complication Diseases 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655526P | 2012-06-05 | 2012-06-05 | |
| US61/655,526 | 2012-06-05 | ||
| PCT/US2013/044058 WO2013184650A2 (en) | 2012-06-05 | 2013-06-04 | Treatment of ocular inflammatory diseases using laquinimod |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158674A Division JP2018024677A (ja) | 2012-06-05 | 2017-08-21 | ラキニモドを使用する眼炎症性疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015523986A JP2015523986A (ja) | 2015-08-20 |
| JP2015523986A5 true JP2015523986A5 (https=) | 2016-07-21 |
Family
ID=49671002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516113A Pending JP2015523986A (ja) | 2012-06-05 | 2013-06-04 | ラキニモドを使用する眼炎症性疾患の治療 |
| JP2017158674A Withdrawn JP2018024677A (ja) | 2012-06-05 | 2017-08-21 | ラキニモドを使用する眼炎症性疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158674A Withdrawn JP2018024677A (ja) | 2012-06-05 | 2017-08-21 | ラキニモドを使用する眼炎症性疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20130324574A1 (https=) |
| EP (1) | EP2854767A4 (https=) |
| JP (2) | JP2015523986A (https=) |
| AR (1) | AR092842A1 (https=) |
| CA (1) | CA2874767A1 (https=) |
| IL (1) | IL235874A0 (https=) |
| RU (1) | RU2014151992A (https=) |
| TW (1) | TW201400117A (https=) |
| UY (1) | UY34843A (https=) |
| WO (1) | WO2013184650A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN105960238A (zh) * | 2013-11-15 | 2016-09-21 | 梯瓦制药工业有限公司 | 使用拉喹莫德治疗青光眼 |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| PL3886858T3 (pl) * | 2019-12-19 | 2022-08-29 | Active Biotech Ab | Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem |
| WO2022207773A1 (en) * | 2021-04-01 | 2022-10-06 | Active Biotech Ab | Laquinimod formulation for ocular use |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| US6852323B2 (en) | 2000-07-21 | 2005-02-08 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| AR044927A1 (es) | 2003-06-25 | 2005-10-12 | Elan Pharm Inc | Metodos y composiciones para tratar la artritis reumatoidea |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2005097162A2 (en) | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and their use |
| CA2565545A1 (en) | 2004-05-06 | 2005-12-08 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| US20090048181A1 (en) | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EA015860B1 (ru) | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US7884208B2 (en) | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| ZA200803327B (en) | 2005-10-26 | 2009-09-30 | Serono Lab | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| ES2752137T3 (es) | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| US8410115B2 (en) | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| WO2007103112A2 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| RS52169B (sr) | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| EP1886996A1 (en) | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| ATE510538T1 (de) | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
| WO2008085484A2 (en) | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
| CA2970273C (en) | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| US8354428B2 (en) | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| RS54328B1 (sr) | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| PT2467372T (pt) | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| TWI618539B (zh) * | 2009-12-15 | 2018-03-21 | 遠景生物製藥股份有限公司 | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 |
| NZ602512A (en) | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| JP5819328B2 (ja) | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
| CN102791130B (zh) | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| US20130045886A1 (en) | 2010-03-08 | 2013-02-21 | Gary Whittaker | Methods For Diagnosing Feline Coronavirus Infections |
| US20130209463A1 (en) * | 2010-06-30 | 2013-08-15 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| EP3056205A1 (en) | 2010-07-09 | 2016-08-17 | Teva Pharmaceutical Industries, Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| WO2012075490A2 (en) | 2010-12-03 | 2012-06-07 | Duke University | Anti-podoplanin antibodies and methods of use |
| WO2012078591A1 (en) | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| WO2013016686A1 (en) | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| EA201490377A1 (ru) | 2011-07-28 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201804997A (zh) | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140107154A1 (en) | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
-
2013
- 2013-05-31 TW TW102119465A patent/TW201400117A/zh unknown
- 2013-06-03 AR ARP130101957A patent/AR092842A1/es unknown
- 2013-06-03 UY UY0001034843A patent/UY34843A/es not_active Application Discontinuation
- 2013-06-04 RU RU2014151992A patent/RU2014151992A/ru not_active Application Discontinuation
- 2013-06-04 JP JP2015516113A patent/JP2015523986A/ja active Pending
- 2013-06-04 US US13/909,403 patent/US20130324574A1/en not_active Abandoned
- 2013-06-04 EP EP13800213.4A patent/EP2854767A4/en not_active Withdrawn
- 2013-06-04 CA CA2874767A patent/CA2874767A1/en not_active Abandoned
- 2013-06-04 WO PCT/US2013/044058 patent/WO2013184650A2/en not_active Ceased
-
2014
- 2014-11-24 IL IL235874A patent/IL235874A0/en unknown
-
2017
- 2017-04-28 US US15/582,162 patent/US20170231971A1/en not_active Abandoned
- 2017-08-07 US US15/670,684 patent/US20170333420A1/en not_active Abandoned
- 2017-08-21 JP JP2017158674A patent/JP2018024677A/ja not_active Withdrawn
- 2017-11-17 US US15/816,402 patent/US11654140B2/en active Active
-
2021
- 2021-08-27 US US17/459,971 patent/US20210386731A1/en not_active Abandoned
-
2024
- 2024-07-16 US US18/774,728 patent/US20250134881A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5579079B2 (ja) | 黄斑浮腫治療用ジフルプレドナート点眼剤 | |
| Zaczek et al. | Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery | |
| JP5557408B1 (ja) | 眼底疾患治療剤 | |
| JP2015523986A5 (https=) | ||
| JP6249194B2 (ja) | レバミピド又はこの前駆体を含む眼球乾燥症候群の予防又は治療のための経口用薬剤学的組成物 | |
| Hall | Acute angle-closure glaucoma as a complication of combined β-agonist and ipratropium bromide therapy in the emergency department | |
| Fathilah et al. | The Jarisch-Herxheimer reaction in ocular syphilis | |
| Yin et al. | Facilitation of amblyopia management by laser in situ keratomileusis in high anisometropic hyperopic and myopic children | |
| US20130317036A1 (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| AU2020399259A1 (en) | Treatments of diabetic macular edema and impaired visual acuity | |
| KR20230170963A (ko) | 근시 치료용 방법과 약학 조성물 | |
| JP6116714B2 (ja) | 眼科炎症疾患治療用点眼剤組成物及びその製造方法 | |
| Cole et al. | Bilateral acute angle-closure glaucoma in a migraine patient receiving topiramate: a case report | |
| RU2014151992A (ru) | Лечение воспалительных заболеваний глаз с применением лахинимода | |
| Gay et al. | Topical sympatholytic therapy for pathologic lid retraction | |
| Steigerwalt et al. | Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids | |
| Park et al. | Evaluation of the mydriatic effect of intracameral lidocaine hydrochloride injection in eyes of clinically normal dogs | |
| KR20240050324A (ko) | 빈포세틴을 사용한 근시치료방법 | |
| Khan et al. | Beyond the local effect: an examination of cardiovascular and other systemic complications of ophthalmologic drugs | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
| Findl | Redefining the treatment paradigm for post-operative inflammation control–the role of topical non-steroidal anti-inflammatory drugs | |
| RU2393823C1 (ru) | Устройство для локальной доставки лекарственных растворов, применяемых в офтальмологии | |
| Anderson et al. | Potential use of bilberry for dry eye relief | |
| Popović-Suić et al. | Early effects of intravitreal bevacizumab (Avastin) for neovascular glaucoma |